Cui, Pin
Zhou, Xiaozhou
Xu, Shu
He, Weihuang
Huang, Guozeng
Xiong, Yong
Zhang, Chuxin
Chang, Tingmin
Feng, Mingji
Lai, Hanming
Pan, Yi
Funding for this research was provided by:
Shenzhen Science and Technology Innovation Program (No. JCYJ20210324120405015, No. JCYJ20210324120405015)
Natural Science Foundation of China (No. 82374531)
Article History
Received: 11 September 2023
Accepted: 19 February 2024
First Online: 27 February 2024
Declarations
:
: Protocol for HCC sample collection of this study was approved by the ethics committee of Shenzhen Traditional Chinese Medicine Hospital with Approval No. 201858 and protocols for all other types of sample collection were approved by the ethics committee of University of Chinese Academy of Sciences Shenzhen Hospital with Approval No. LL-KT-2022053. All of them were performed following international standards of good clinical practice.
: Not applicable.
: Pin Cui is the founder and Chief Technology Officer of Shenzhen Rapha Biotechnology Inc., Shenzhen, China. Weihuang He, Mingji Feng, and Hanming Lai are employees of Shenzhen Rapha Biotechnology Inc. The remaining authors declare no conflicts of interest.